• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
In vitro evaluation of DuP 105 and DuP 721, two new oxazolidinone antimicrobial agents.新型恶唑烷酮类抗菌剂DuP 105和DuP 721的体外评价
Antimicrob Agents Chemother. 1988 Jan;32(1):150-2. doi: 10.1128/AAC.32.1.150.
2
Antibacterial oxazolidinones. In vitro activity of a new analogue, E3709.
Diagn Microbiol Infect Dis. 1992 Sep-Oct;15(7):621-5. doi: 10.1016/0732-8893(90)90040-3.
3
Comparative in vitro activity of the new oxazolidinones DuP 721 and DuP 105 against staphylococci and streptococci.
Eur J Clin Microbiol Infect Dis. 1989 Mar;8(3):256-60. doi: 10.1007/BF01965273.
4
In vitro activities of two oxazolidinone antimicrobial agents, DuP 721 and DuP 105.两种恶唑烷酮类抗菌剂DuP 721和DuP 105的体外活性
Antimicrob Agents Chemother. 1988 Apr;32(4):580-3. doi: 10.1128/AAC.32.4.580.
5
Oxazolidinones, a new class of synthetic antibacterial agents: in vitro and in vivo activities of DuP 105 and DuP 721.恶唑烷酮类，一类新型合成抗菌剂：DuP 105和DuP 721的体外及体内活性
Antimicrob Agents Chemother. 1987 Nov;31(11):1791-7. doi: 10.1128/AAC.31.11.1791.
6
Activity and mechanism of action of DuP 105 and DuP 721, new oxazolidinone compounds.新型恶唑烷酮化合物DuP 105和DuP 721的活性及作用机制
J Antimicrob Chemother. 1988 Jun;21(6):721-30. doi: 10.1093/jac/21.6.721.
7
In-vitro microbiological activities of DuP 105 and DuP 721, novel synthetic oxazolidinones.新型合成恶唑烷酮DuP 105和DuP 721的体外微生物活性
J Antimicrob Chemother. 1988 Jun;21(6):711-20. doi: 10.1093/jac/21.6.711.
8
In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci.利奈唑胺对包括耐万古霉素肠球菌在内的重要革兰氏阳性菌病原体的体外活性。
Antimicrob Agents Chemother. 1999 Aug;43(8):2059-62. doi: 10.1128/AAC.43.8.2059.
9
In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.新型恶唑烷酮类抗菌剂U-100592和U-100766的体外活性
Antimicrob Agents Chemother. 1996 Apr;40(4):839-45. doi: 10.1128/AAC.40.4.839.
10
In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones.两种新型氟化恶唑烷酮U-100592和U-100766的体外抗菌活性及抗菌谱
Antimicrob Agents Chemother. 1996 Mar;40(3):720-6. doi: 10.1128/AAC.40.3.720.

引用本文的文献

1
Syntheses and biological studies of novel spiropiperazinyl oxazolidinone antibacterial agents using a spirocyclic diene derived acylnitroso Diels-Alder reaction.新型螺环哌嗪基恶唑烷酮类抗菌剂的合成及生物研究：利用螺环二烯衍生的酰基亚硝酰 Diels-Alder 反应。
Bioorg Med Chem. 2012 Jun 1;20(11):3422-8. doi: 10.1016/j.bmc.2012.04.026. Epub 2012 Apr 18.
2
Mode of action of Ranbezolid against staphylococci and structural modeling studies of its interaction with ribosomes.瑞贝唑胺对葡萄球菌的作用机制及其与核糖体相互作用的结构建模研究
Antimicrob Agents Chemother. 2009 Apr;53(4):1427-33. doi: 10.1128/AAC.00887-08. Epub 2008 Dec 15.
3
A critical review of oxazolidinones: an alternative or replacement for glycopeptides and streptogramins?恶唑烷酮类药物的批判性综述：糖肽类和链阳菌素类的替代物还是替代品？
Can J Infect Dis. 2001 Nov;12(6):379-90. doi: 10.1155/2001/260651.
4
Clinical experience with linezolid in the treatment of resistant gram-positive infections.利奈唑胺治疗耐药革兰氏阳性菌感染的临床经验。
J Natl Med Assoc. 2001 Oct;93(10):386-91.
5
Ribosomes from an oxazolidinone-resistant mutant confer resistance to eperezolid in a Staphylococcus aureus cell-free transcription-translation assay.在金黄色葡萄球菌无细胞转录-翻译试验中，来自恶唑烷酮耐药突变体的核糖体赋予对依哌唑胺的抗性。
Antimicrob Agents Chemother. 1998 Apr;42(4):947-50. doi: 10.1128/AAC.42.4.947.
6
Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium.恶唑烷酮类化合物依哌唑胺（PNU - 100592）和利奈唑胺（PNU - 100766）与万古霉素相比，对金黄色葡萄球菌、凝固酶阴性葡萄球菌、粪肠球菌和屎肠球菌的体外比较活性及抗生素后效应。
Antimicrob Agents Chemother. 1998 Mar;42(3):721-4. doi: 10.1128/AAC.42.3.721.
7
The oxazolidinone eperezolid binds to the 50S ribosomal subunit and competes with binding of chloramphenicol and lincomycin.恶唑烷酮类药物依哌唑胺与50S核糖体亚基结合，并与氯霉素和林可霉素的结合相互竞争。
Antimicrob Agents Chemother. 1997 Oct;41(10):2127-31. doi: 10.1128/AAC.41.10.2127.
8
In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species.恶唑烷酮类抗生素U-100592和U-100766对金黄色葡萄球菌和凝固酶阴性葡萄球菌的体外活性
Antimicrob Agents Chemother. 1997 Feb;41(2):465-7. doi: 10.1128/AAC.41.2.465.
9
In vitro activities of oxazolidinone compounds U100592 and U100766 against Staphylococcus aureus and Staphylococcus epidermidis.恶唑烷酮类化合物U100592和U100766对金黄色葡萄球菌和表皮葡萄球菌的体外活性
Antimicrob Agents Chemother. 1996 Mar;40(3):799-801. doi: 10.1128/AAC.40.3.799.
10
In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents.新型恶唑烷酮类抗菌剂U-100592和U-100766的体外活性
Antimicrob Agents Chemother. 1996 Apr;40(4):839-45. doi: 10.1128/AAC.40.4.839.

新型恶唑烷酮类抗菌剂DuP 105和DuP 721的体外评价

In vitro evaluation of DuP 105 and DuP 721, two new oxazolidinone antimicrobial agents.

作者信息

Barry A L

机构信息

Clinical Microbiology Institute, Tualatin, Oregon 97062.

出版信息

Antimicrob Agents Chemother. 1988 Jan;32(1):150-2. doi: 10.1128/AAC.32.1.150.

DOI:10.1128/AAC.32.1.150
PMID:3348606
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC172119/
Abstract

DuP 105 and DuP 721 are two members of the oxazolidinones, a new class of synthetic antimicrobial agents with activity against gram-positive bacteria. In vitro tests compared the two new drugs with five other antimicrobial agents against 216 gram-positive isolates representing 4 genera and 10 species. DuP 721 MICs for 50% of the strains tested (MIC50s) ranged from 2.0 to 8.0 micrograms/ml, DuP 105 MIC50S ranged from 4.0 to 16 micrograms/ml, and vancomycin MIC50S ranged from 0.25 to 1.0 microgram/ml. Methicillin-resistant and -susceptible staphylococci were susceptible to ciprofloxacin, vancomycin, and DuP 721.

摘要

DuP 105和DuP 721是恶唑烷酮类药物中的两个成员，恶唑烷酮类是一类新型的合成抗菌剂，对革兰氏阳性菌具有活性。体外试验将这两种新药与其他五种抗菌剂针对代表4个属和10个种的216株革兰氏阳性分离株进行了比较。DuP 721对50%受试菌株的最低抑菌浓度（MIC50）范围为2.0至8.0微克/毫升，DuP 105的MIC50范围为4.0至16微克/毫升，而万古霉素的MIC50范围为0.25至1.0微克/毫升。耐甲氧西林和对甲氧西林敏感的葡萄球菌对环丙沙星、万古霉素和DuP 721敏感。